赛诺医疗公告，近日，公司收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》。产品 名称为药物洗脱支架系统，适用于改善局部缺血型心脏病患者的血管狭窄症状。该产品为赛诺医疗自主 研发并生产，其获批将丰富公司产品组合，满足市场需求，提升核心竞争力。 ...

结构及组成：药物洗脱支架系统由药物涂层支架和快速交换球囊导管输送系统组成。药物涂层支架以 L605钴铬合金支架为基体，表面涂覆底部涂层和含药高分子涂层。底部涂层材料为聚甲基丙烯酸丁酯 （PBuMA），该涂层不可降解；药物涂层由雷帕霉素药物和聚乳酸-羟基乙酸（PLGA）组成，为可降 解涂层。支架药物剂量密度为1.20μg/mm2；载药量为59μg～324μg。输送系统由TIP头、球囊、 Marker、球囊内管、球囊外管和手柄组成。产品经过电子束灭菌，一次性使用。货架有效期18个月。 适用范围：该产品适用于参考1.血管直径为2.25～4.00mm，适用的病变长度≤40mm；2.参考血管直径为 4.50～5.00mm，适用的病变长度≤30mm；用于改善局部缺血型心脏病患者的血管狭窄症状。 格隆汇2月4日丨赛诺医疗(688108.SH)公布，近日，公司收到国家药品监督管理局颁发的《中华人民共 和国医疗器械注册证》，产品名称：药物洗脱支架系统，注册证编号：国械注准20263130263。 本次获得《医疗器械注册证》的药物洗脱支架系统，是由我公司自主研发并进行生产的一款冠脉支架类 产品。该产品是一个预装的药物洗脱支架系统 ...

格隆汇2月4日丨赛诺医疗(688108.SH)公布，近日，公司收到国家药品监督管理局颁发的《中华人民共 和国医疗器械注册证》，产品名称：药物洗脱支架系统，注册证编号：国械注准20263130263。 结构及组成：药物洗脱支架系统由药物涂层支架和快速交换球囊导管输送系统组成。药物涂层支架以 L605钴铬合金支架为基体，表面涂覆底部涂层和含药高分子涂层。底部涂层材料为聚甲基丙烯酸丁酯 （PBuMA），该涂层不可降解；药物涂层由雷帕霉素药物和聚乳酸-羟基乙酸（PLGA）组成，为可降 解涂层。支架药物剂量密度为1.20μg/mm2；载药量为59μg～324μg。输送系统由TIP头、球囊、 Marker、球囊内管、球囊外管和手柄组成。产品经过电子束灭菌，一次性使用。货架有效期18个月。 适用范围：该产品适用于参考1.血管直径为2.25～4.00mm，适用的病变长度≤40mm；2.参考血管直径为 4.50～5.00mm，适用的病变长度≤30mm；用于改善局部缺血型心脏病患者的血管狭窄症状。 本次获得《医疗器械注册证》的药物洗脱支架系统，是由我公司自主研发并进行生产的一款冠脉支架类 产品。该产品是一个预装的药物洗脱支架系统 ...

Core Viewpoint - A total of 371 companies on the Sci-Tech Innovation Board have issued performance forecasts for 2025, with 125 companies expecting losses, 82 expecting profit increases, 70 expecting reduced losses, 50 expecting profits, 43 expecting declines, and 1 expecting stable performance [1][6]. Performance Forecast Summary - Among the 371 companies, 82 are expected to increase profits, and 50 are expected to be profitable, resulting in a total of 132 companies with positive forecasts, accounting for 35.58% of the total [1][6]. - 88 companies are projected to have a net profit increase of over 100%, while 33 companies are expected to see an increase between 50% and 100% [1][6]. Individual Company Highlights - Yuanjie Technology is expected to have the highest net profit increase, with a median increase of 3197.55% [1][6]. - Sino Medical and Huafeng Technology are projected to have median net profit increases of 3000.00% and 2145.01%, ranking second and third respectively [1][6]. Industry Performance Insights - The industries with companies expecting net profit increases of over 50% include electronics (31 companies), machinery (24 companies), and biomedicine (22 companies) [1][6]. Stock Performance Overview - Sci-Tech Innovation Board stocks with high expected growth have averaged a 15.69% increase this year [2][6]. - The stock with the highest increase is Zhuoyi Information, which has risen by 92.10%, followed by Zhenlei Technology and Helin Micro-Nano with increases of 68.00% and 67.47% respectively [2][6]. Capital Flow Analysis - In the past five days, the stocks with significant net inflows include Guodun Quantum (5.72 billion), Green Harmony (3.08 billion), and Jieput (2.46 billion) [7]. - Conversely, stocks with significant net outflows include Cambrian (50.99 billion), Baiwei Storage (16.59 billion), and Chip Micro (5.98 billion) [7].

Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

截至2026年1月30日收盘，赛诺医疗(688108)报收于24.33元，上涨0.95%，换手率3.73%，成交量15.59万 手，成交额3.73亿元。 当日关注点 交易信息汇总 资金流向 1月30日主力资金净流出419.74万元，占总成交额1.13%；游资资金净流入1266.56万元，占总成交额 3.4%；散户资金净流出846.82万元，占总成交额2.27%。 业绩披露要点 业绩预告 赛诺医疗发布业绩预告，预计2025年全年扣非后净利润盈利3000万元至3580万元。赛诺医疗发布业绩预 告，预计2025年全年归属净利润盈利4300万元至5000万元。赛诺医疗发布业绩预告，预计2025年全年营 业收入5.19亿元至5.26亿元。 公司公告汇总 赛诺医疗科学技术股份有限公司2025年度业绩预增公告 赛诺医疗预计2025年度营业收入为51,940万元至52,600万元，同比增长13%至15%；归属于上市公司股 东的净利润为4,300万元至5,000万元，同比增长2,767%至3,233%；扣除非经常性损益后的净利润为3,000 万元至3,580万元，实现扭亏为盈。业绩增长主要得益于冠脉介入和神经介入产品销量增长、 ...

通化东宝的2025年业绩增幅，预计也将超过30倍。经公司财务部门初步测算，预计2025年归属净利润约 12.42亿元，将实现扭亏为盈。 2025年，A股医药股的业绩"冷暖交织"。Wind数据显示，截至2月1日，共有283只医药股"剧透"2025年 的业绩情况。按预告净利润上限看，共有160股的归属净利润同比增长，其中赛诺医疗成为A股药企的 净利"预增王"，最高预增超32倍。在过半数企业业绩预增的同时，也有超120家企业的业绩预减，其中 更有39股面临上市后的首次亏损，不乏智飞生物、珍宝岛、新诺威等知名企业。此外，通过业绩预告可 以发现，创新药领域正悄然迎来破晓时分。其中，荣昌生物、诺诚健华等企业实现扭亏为盈。君实生 物、盟科药业等创新药企虽未盈利，但减亏趋势明显。 赛诺医疗成"预增王" Wind数据显示，截至2月1日，按预告净利润上限看，283只披露2025年业绩预告的医药股中，共有160 股实现归属净利润同比增长。 业绩预增的个股中，药明康德、翰宇药业、康希诺、泰格医药、三生国健等65股的预告净利润同比增长 上限超100%，赛诺医疗、通化东宝、回盛生物3股的业绩增幅超10倍。 其中，赛诺医疗以最高超32倍的 ...

每经记者｜蔡鼎 每经编辑｜董兴生 A股2025年年度业绩预告披露正式收官。 Wind金融终端数据显示，截至1月31日，除70多家已披露年报的公司外，A股市场已有约3000家上市公司对外披露了2025年度业绩预告，覆盖范围广泛，为 市场判断全年业绩走势提供了重要参考。 具体来看，沪深北三市共有2956家公司披露了2025年度业绩预告。其中，有705家公司业绩预增、420家公司业绩预减、987家公司续亏，另有374家公司预计 扭亏为盈。 总的来看，剔除扭亏为盈的上市公司后，宁波富邦（SH600768）同比预增超30倍居首，万科A（SZ000002）预计亏损820亿元，成"亏损王"。 剔除扭亏为盈的上市公司后，宁波富邦以3099.59%~4379.43%的归母净利润增幅位居榜首，成为业绩预告中的黑马。公告显示，宁波富邦预计2025年实现归 母净利润5000万元~7000万元。不过，据公司公告，其归母净利润大增系非经常性损益较上年同期大幅增长所致，主要原因为公司将持有的宁波中华纸业有 限公司2.5%股权以3.7亿元的价格转让给金光纸业（中国）投资有限公司，导致公司所持的宁波中华纸业有限公司2.5%股权公允价值变动产生 ...

Core Viewpoint - The performance of A-share pharmaceutical stocks in 2025 shows a mixed outlook, with 283 companies disclosing earnings forecasts, where 160 companies expect profit growth while over 120 companies anticipate profit declines, indicating a significant divergence in the industry [1][3]. Group 1: Profit Growth - Among the 283 pharmaceutical stocks, 160 companies are expected to see a year-on-year increase in net profit, with Sino Medical (688108) leading the pack with a projected increase of over 32 times [1][3]. - Sino Medical forecasts a net profit of 43 million to 50 million yuan for 2025, representing a year-on-year growth of 2,767% to 3,233% [3]. - Other notable companies with significant profit growth include WuXi AppTec, Hanyu Pharmaceutical, and Kangxino, with 65 companies projecting a net profit increase of over 100% [3][4]. Group 2: Profit Decline - Over 120 companies are expected to report a decline in net profit for 2025, with 39 companies facing their first losses since listing, including well-known firms like Zhifei Biological and Zhenbao Island [1][5]. - Zhifei Biological anticipates a net loss of approximately 10.698 billion to 13.726 billion yuan, marking a year-on-year decline of 630% to 780% [6][7]. - The decline in the vaccine sector is attributed to decreased public willingness to vaccinate and increased vaccine hesitancy, leading to significant performance pressure across the industry [7][8]. Group 3: Innovative Drug Companies - Several innovative drug companies are reporting positive trends, with some achieving profitability or significantly reducing losses. For instance, Nocren Pharmaceutical is expected to turn a profit for the first time, projecting a net profit of around 633 million yuan [10]. - Rongchang Biopharmaceutical is also expected to turn a profit, with a projected net profit of approximately 716 million yuan, driven by strong sales of core products [10]. - Companies like Junshi Biosciences and Amgen have not yet achieved profitability but are showing a clear trend of reduced losses, indicating a gradual transition towards commercialization and revenue growth in the innovative drug sector [11].

公司公告汇总 赛诺医疗预计2025年度营业收入为51,940万元至52,600万元，同比增长13%至15%；归属于上市公司股 东的净利润为4,300万元至5,000万元，同比增长2,767%至3,233%；扣除非经常性损益后的净利润为3,000 万元至3,580万元，实现扭亏为盈。业绩增长主要得益于冠脉介入和神经介入产品销量增长、成本下降 及费用控制。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 业绩披露要点：赛诺医疗预计2025年归属净利润同比增长2,767%至3,233%。 业绩披露要点：2025年营业收入预计为5.19亿元至5.26亿元，同比增长13%至15%。 公司公告汇总：赛诺医疗2025年扣非后净利润预计为3,000万元至3,580万元，实现扭亏为盈。 本周关注点 业绩披露要点 赛诺医疗发布业绩预告，预计2025年全年营业收入5.19亿元至5.26亿元。预计2025年全年归属净利润盈 利4300万元至5000万元，同比增长2,767%至3,233%。扣非后净利润预计盈利3000万元至3580万元。 截至2026年1月 ...